Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone
US10463716B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 13, 2015 |
| Grant date | Nov 5, 2019 |
| Priority date | — |
| Expiry date | Oct 13, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention generally to methods of treating subjects suffering from a cardiac condition or having a risk factor for developing a cardiac condition by administering an ELA peptide or fusion protein to a subject in need. The invention relates to fusion proteins of Fc-ELA-32 and Fc-ELA-21 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of cardiac conditions. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.